It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Understanding the impact of guide RNA (gRNA) and genomic locus on CRISPR-Cas9 activity is crucial to design effective gene editing assays. However, it is challenging to profile Cas9 activity in the endogenous cellular environment. Here we leverage our TRIP technology to integrate ~ 1k barcoded reporter genes in the genomes of mouse embryonic stem cells. We target the integrated reporters (IRs) using RNA-guided Cas9 and characterize induced mutations by sequencing. We report that gRNA-sequence and IR locus explain most variation in mutation efficiency. Predominant insertions of a gRNA-specific nucleotide are consistent with template-dependent repair of staggered DNA ends with 1-bp 5′ overhangs. We confirm that such staggered ends are induced by Cas9 in mouse pre-B cells. To explain observed insertions, we propose a model generating primarily blunt and occasionally staggered DNA ends. Mutation patterns indicate that gRNA-sequence controls the fraction of staggered ends, which could be used to optimize Cas9-based insertion efficiency.
Designing effective genome engineering strategies requires an understanding of the impact that genomic locus has on CRISPR-Cas9 activity. Here the authors use TRIP integrations to profile editing outcomes genome-wide and observe that gRNA sequence influences the structure of the double strand break.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Gonçalves, Joana P 2
; Akhtar Waseem 1 ; de Jong Johann 3 ; Pindyurin, Alexey V 4
; Wessels Lodewyk F A 2 ; van Lohuizen Maarten 1 1 Oncode and The Netherlands Cancer Institute, Division of Molecular Genetics, Amsterdam, The Netherlands (GRID:grid.430814.a)
2 Delft University of Technology, Department of Intelligent Systems, Delft, The Netherlands (GRID:grid.5292.c) (ISNI:0000 0001 2097 4740); Oncode and The Netherlands Cancer Institute, Division of Molecular Carcinogenesis, Amsterdam, The Netherlands (GRID:grid.430814.a)
3 Oncode and The Netherlands Cancer Institute, Division of Molecular Carcinogenesis, Amsterdam, The Netherlands (GRID:grid.430814.a); UCB Biosciences GmbH, Data & Translational Sciences Group, Monheim am Rhein, Germany (GRID:grid.420204.0) (ISNI:0000 0004 0455 9792)
4 Siberian Branch of Russian Academy of Sciences, Institute of Molecular and Cellular Biology, Novosibirsk, Russia (GRID:grid.415877.8) (ISNI:0000 0001 2254 1834); Oncode and The Netherlands Cancer Institute, Division of Gene Regulation, Amsterdam, The Netherlands (GRID:grid.430814.a)




